Recent Advances in the Treatment of Advanced HER2+ Breast Cancer: SABCS 2024 - Episode 7
Panelists discuss how patients with HER2+ breast cancer frequently develop brain metastases, with recent pivotal trials such as HER2CLIMB and DESTINY-Breast03 demonstrating improved intracranial responses with newer agents such as tucatinib, and how trastuzumab deruxtecan leads to evolving standards of care (SOC) that now incorporate these targeted therapies alongside traditional local therapies.
Video content above is prompted by the following:
Provide a brief overview of the epidemiology and treatment landscape surrounding HER2+ advanced breast cancer with brain metastases. Briefly comment on the current SOC and pivotal trials that have helped shape this treatment space: